CureVac’s experimental COVID-19 vaccine generated an immune response in humans, the German biotech firm said on Monday.
“We are very encouraged by the interim Phase I data,” Chief Executive Officer Franz-Werner Haas said in a statement.
They are also using the same messenger RNA (mRNA) that was being used by Moderna as well as BioNTech and its partner Pfizer for the vaccine, mass testing of which was started on humans in late July.
CureVac said its potential vaccine, known as CVnCoV, was generally well tolerated, and trial results strongly supported the company’s plans to launch the final stage of testing involving about 30,000 participants before the end of the year.
ALSO READ| Covid-19 Vaccine: Pfizer, BioNTech Agree To Offer BNT162 To US Agencies For Free As Part Of ‘Operation Warp Speed’ Deal
German biotech investor Dietmar Hopp is backing CureVac in this process. Gates Foundation and GlaxoSmithKline, said the volunteers developed a level of neutralising antibodies on equality with people who had recovered from a serious case of COVID-19.
The pandemic, which has affected more than 1.2 million lives globally, has triggered a scramble to develop a vaccine with about 45 experimental compounds being tested on humans.
The University of Oxford and AstraZeneca’s partnership is also among the leading contenders with late-stage trial results expected this year. Their candidate is based on another virus, rather than mRNA, to deliver genetic instructions into the body for an immunisation effect.
Anthony Fauci, the top U.S. infectious diseases expert, said on Thursday that the first doses of a safe and effective coronavirus vaccine will likely become available to some high-risk Americans in late December or early January.
CureVac is looking for a partner and it hopes of offering a vaccine at much lower doses than its mRNA competitors.
Moderna, like BioNTech expects to have the first efficacy data from its mass trial this month. It is testing a 100 microgram shot that has also been shown to trigger an antibody response above that of recovered patients.
ALSO READ| COVID-19 Vaccine: Pfizer Targets Emergency Approval Next Month, Says CEO In An Open Letter
A CureVac spokesman said even at 12 micrograms its dosage was still a relatively low.
CureVac has said it was looking into a potential partnership with a major pharmaceutical company as it seeks to scale up development, production and distribution. The spokesman said on Monday that the firm was looking into various options.
The 20-year-old company, which went public on the Nasdaq exchange in August, said its Phase I study has so far enrolled more than 250 healthy individuals aged 18 to 60 years in Germany and Belgium.
It said its inoculation appears to also generate T cells against the coronavirus, another key indicator of an effective immune system arsenal, but more analysis of this was ongoing.
CureVac said side effects occurred mostly after the second injection of its two-dose regimen and included fatigue, headache, chills, muscle pain and, to a lesser extent, fever.